Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jaimie D. Sixsmith"'
Autor:
Jaimie D. Sixsmith, Megan Murray, Nathan D. Hicks, Maha R. Farhat, Sarah M. Fortune, Roger Calderon
Publikováno v:
Journal of Antimicrobial Chemotherapy. 74:1477-1483
OBJECTIVES: Drug-resistant TB remains a public health challenge. Rifamycins are among the most potent anti-TB drugs. They are known to target the RpoB subunit of RNA polymerase; however, our understanding of how rifamycin resistance is genetically en
Autor:
Manjunatha M Venkataswamy, Tony W Ng, Shalu S Kharkwal, Leandro J Carreño, Alison J Johnson, Shajo Kunnath-Velayudhan, Zheng Liu, Robert Bittman, Peter J Jervis, Liam R Cox, Gurdyal S Besra, Xiangshu Wen, Weiming Yuan, Moriya Tsuji, Xiangming Li, David D Ho, John Chan, Sunhee Lee, Richard Frothingham, Barton F Haynes, Michael W Panas, Geoffrey O Gillard, Jaimie D Sixsmith, Birgit Korioth-Schmitz, Joern E Schmitz, Michelle H Larsen, William R Jacobs, Steven A Porcelli
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e108383 (2014)
Recombinant Mycobacterium bovis bacillus Calmette-Guèrin (rBCG) has been explored as a vector for vaccines against HIV because of its ability to induce long lasting humoral and cell mediated immune responses. To maximize the potential for rBCG vacci
Externí odkaz:
https://doaj.org/article/90e45a31ded54c5cbca2c3231d0f0e54
Autor:
Sydney Stanley, Sarah M. Fortune, Michael C. Chao, Samantha R. Giffen, Qingyun Liu, Ian D. Wolf, Jessica Brown, Jaimie D. Sixsmith, Nathan D. Hicks, Peter H. Culviner, Charles L. Dulberger
Publikováno v:
PLoS Pathogens
PLoS Pathogens, Vol 16, Iss 11, p e1009063 (2020)
PLoS Pathogens, Vol 16, Iss 11, p e1009063 (2020)
Genomic dissection of antibiotic resistance in bacterial pathogens has largely focused on genetic changes conferring growth above a single critical concentration of drug. However, reduced susceptibility to antibiotics—even below this breakpoint—i
Autor:
Casey C. Perley, Richard Frothingham, Norman L. Letvin, Eva M. Click, Birgit Korioth-Schmitz, Sunhee Lee, Jaimie D. Sixsmith
Publikováno v:
Vaccine. 33(42):5715-5722
Background A recombinant Mycobacterium bovis BCG (rBCG) vector expressing HIV transgenes is an attractive candidate as a dual vaccine against HIV and TB. However, pre-existing immune responses to mycobacteria may influence immune responses to rBCG. W
Autor:
Jaimie D. Sixsmith, Sunhee Lee, Rose Asrican, Barton F. Haynes, Swati D. G. Rayasam, Amanda E. Jimenez, Linda Berney-Meyer, Kim Vermeul, Steven A. Porcelli, William R. Jacobs, David M. Tobin, Priyadharshini Pajanirassa, Leslie Magtanong, Regy Lukose, Michelle H. Larsen, So-Yon Lim, Joern E. Schmitz, Sommer J. R. Souther, Richard Frothingham, Ching Ju Chen, Bryan E. Hart, Tony W. Ng, Sarah A. Seay, Joseph W. Saelens
Publikováno v:
Clinical and Vaccine Immunology. 22:726-741
The well-established safety profile of the tuberculosis vaccine strain,Mycobacterium bovisbacille Calmette-Guérin (BCG), makes it an attractive vehicle for heterologous expression of antigens from clinically relevant pathogens. However, successful g
Autor:
Geoffrey O. Gillard, Sunhee Lee, Shana T. Shields, Norman L. Letvin, Keri Ann White, William R. Jacobs, Birgit Korioth-Schmitz, Joern E. Schmitz, Michael W. Panas, Jaimie D. Sixsmith, Steven A. Porcelli, Barton F. Haynes, Brian T. Moy
Publikováno v:
Infection and immunity. 82(12)
Mycobacteria, the etiological agents of tuberculosis and leprosy, have coevolved with mammals for millions of years and have numerous ways of suppressing their host's immune response. It has been suggested that mycobacteria may contain genes that red
Autor:
Barton F. Haynes, William R. Jacobs, C. Todd De Marco, Sunhee Lee, Joern E. Schmitz, Geoffrey O. Gillard, Michael W. Panas, Georgia D. Tomaras, Norman L. Letvin, Christy L. Lavine, Linh Mach, Steven A. Porcelli, Birgit Korioth-Schmitz, Jaimie D. Sixsmith, Keri Ann White, Richard Frothingham, Michelle A. Lifton, John P. Miller, Harikrishnan Balachandran, Michelle H. Larsen, Connie E. Gee
Live attenuated nonpathogenic Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediates long-lasting immune responses, has been safely administered as a tuberculosis vaccine to billions of humans, and is affordable to produce as a vaccine vector.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41e46de354afd21db00185a31282ab41
https://europepmc.org/articles/PMC4266348/
https://europepmc.org/articles/PMC4266348/
Autor:
Tony W. Ng, Leandro J. Carreño, Birgit Korioth-Schmitz, Joern E. Schmitz, Michelle H. Larsen, Michael W. Panas, Gurdyal S. Besra, Manjunatha M. Venkataswamy, Peter J. Jervis, Barton F. Haynes, David D. Ho, Steven A. Porcelli, John Chan, Alison J. Johnson, Zheng Liu, Moriya Tsuji, William R. Jacobs, Robert Bittman, Jaimie D. Sixsmith, Richard Frothingham, Weiming Yuan, Xiangming Li, Geoffrey O. Gillard, Sunhee Lee, Xiangshu Wen, Liam R. Cox, Shajo Kunnath-Velayudhan, Shalu Sharma Kharkwal
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e108383 (2014)
PLoS ONE
PLoS ONE
Recombinant Mycobacterium bovis bacillus Calmette-Guerin (rBCG) has been explored as a vector for vaccines against HIV because of its ability to induce long lasting humoral and cell mediated immune responses. To maximize the potential for rBCG vaccin